Novel small molecule therapeutics for sickle cell disease: nitric oxide, carbon monoxide, nitrite, and apolipoprotein A-I.

Keyphrases

• Nitric Oxide 100%
• Sickle Cell Disease 100%
• Nitrite 100%
• Small Molecule Therapeutics 100%
• Apolipoprotein A-I (apoA-I) 100%
• Carbon Monoxide 100%
• Vasculopathy 50%
• Nitric Oxide Signaling 33%
• Nitric Oxide Synthase 33%
• Translational Research 16%
• Clinical Development 16%
• Lipoproteins 16%
• Arginine 16%
• Pulmonary Hypertension 16%
• Ongoing Clinical Trials 16%
• Multifactorial Etiology 16%
• Nitric Oxide Bioavailability 16%
• Heme Oxygenase 16%
• Sildenafil 16%
• Priapism 16%
• Exhaled Nitric Oxide 16%
• CAMP Phosphodiesterase 16%
• Phosphodiesterase Type 5 Inhibitors 16%
• Nitrate 16%
• Vascular Treatment 16%
• Leg Ulcer 16%
• Substrate Availability 16%
• CO I 16%
• Therapeutic Field 16%
• Vaso-occlusive Crisis 16%
• Small Molecule Targets 16%
• ApoE-mimetic Peptide 16%
• Vascular Pathophysiology 16%

Medicine and Dentistry

• Nitric Oxide 100%
• Carbon Monoxide 100%
• Nitrite 100%
• Sickle-Cell Disease 100%
• Apolipoprotein A 100%
• Vascular Disease 60%
• Nitric Oxide Synthase 40%
• Apoplexy 20%
• Translational Research 20%
• Pathophysiology 20%
• Arginine 20%
• Clinical Trial 20%
• Morbidity 20%
• Pulmonary Hypertension 20%
• Bioavailability 20%
• Priapism 20%
• Sickle Cell 20%
• Leg Ulcer 20%
• Sildenafil 20%
• Phosphodiesterase V 20%
• Cyclic GMP 20%
• Etiology 20%
• Apolipoprotein 20%
• Hemolysis 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Nitric Oxide 100%
• Carbon Monoxide 100%
• Nitrite 100%
• Sickle Cell Anemia 100%
• Apolipoprotein A 100%
• Vascular Disease 60%
• Nitric Oxide Synthase 40%
• Clinical Trial 20%
• Bioavailability 20%
• Pathophysiology 20%
• Arginine 20%
• Pulmonary Hypertension 20%
• Morbidity 20%
• Cyclic GMP 20%
• Sildenafil 20%
• Cerebrovascular Accident 20%
• Phosphodiesterase V 20%
• Priapism 20%
• Leg Ulcer 20%
• Etiology 20%
• Apolipoprotein 20%
• Hemolysis 20%